TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10432877

Group type: EXPERIMENTAL
Intervention: Calcium oxalate crystals (COCs) in benign lesions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium oxalate crystals (COCs) in malignant lesions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distribution of COCs in benign lesions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distribution of COCs in malignant lesions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Background location of COCs
Number of subjects: 60
Study: 7486094

Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg IV
Number of subjects: 96

Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg IV
Number of subjects: 96
Study: 2150738

Group type: COMPARATOR
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 0 micrograms Sufentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 20 micrograms Sufentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 30 micrograms Sufentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 40 micrograms Sufentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 50 micrograms Sufentanil
Number of subjects: 50
Study: 6903903

Group type: EXPERIMENTAL
Intervention: modeling plus guided practice
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: modeling plus self-monitoring
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: modeling plus peer support
Number of subjects: 130

Group type: COMPARATOR
Intervention: modeling alone
Number of subjects: 130
Study: 31085219

Group type: EXPERIMENTAL
Intervention: CytoSorb hemoadsorption therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 52
Study: 29057795

Group type: EXPERIMENTAL
Intervention: Piceatannol (20 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 27137718

Group type: EXPERIMENTAL
Intervention: 50 mg opicapone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 800 mg opicapone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 64
Study: 24042588

Group type: EXPERIMENTAL
Intervention: Soft silicone-based liner (Mucopren Soft)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hard acrylic resin-based liner (Kooliner)
Number of subjects: 44
Study: 21910337

Group type: EXPERIMENTAL
Intervention: Modified Zigui Decoction (MZD)
Number of subjects: 66
Study: 19375884

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study: 16283320

Group type: EXPERIMENTAL
Intervention: 1 microg alfacalcidol
Number of subjects: 148

Group type: COMPARATOR
Intervention: 880 IU vitamin D plus 1 g calcium carbonate
Number of subjects: 148
Study: 16326667

Group type: EXPERIMENTAL
Intervention: Falls menu-driven incident-reporting system (MDIRS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Existing narrative incident report
Number of subjects: 6
Study: 12043851

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler, 200 microg once every night (q.n.)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler, 100 microg twice‐daily (b.i.d.)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Budesonide (both regimens)
Number of subjects: 288
Study: 10443522

Group type: EXPERIMENTAL
Intervention: PLA rib pins
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alumina rib pins
Number of subjects: 24
Study: 7789372

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction in patients aged ≤ 40 years
Number of subjects: 269

Group type: COMPARATOR
Intervention: Thrombolytic therapy for acute myocardial infarction in patients aged > 40 years
Number of subjects: 269
Study: 2189246

Group type: EXPERIMENTAL
Intervention: Mefloquine (M)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of mefloquine + sulfadoxine + pyrimethamine (MSP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Chloroquine (C)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lowest dose of MSP (10 mg/kg M + 20 mg/kg S + 1.0 mg/kg P)
Number of subjects: 240
Study: 494166

Group type: EXPERIMENTAL
Intervention: Intermittent sequential calf compression
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control (no calf compression)
Number of subjects: 199
Study: 30427582

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis (Arm A)
Number of subjects: 102
Study: 29075107

Group type: EXPERIMENTAL
Intervention: Aerosolized hyaluronan (HA), 150 kDa, administered for 2 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26498221

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 227
Study: 23463769

Group type: EXPERIMENTAL
Intervention: Bear bile capsule and Huangqi granule daily (Group B)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Massaging the children's parotid region and melting vitamin C in their mouth daily (Group A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Massages and vitamin C as prescribed in Group A, and traditional Chinese medicine as prescribed in Group B (Group C)
Number of subjects: 151
Study: 22789511

Group type: EXPERIMENTAL
Intervention: HBVaxPro (Hexavac)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Engerix‐B (Hexavac)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: HBVaxPro (Infanrix‐Hexa)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Engerix‐B (Infanrix‐Hexa)
Number of subjects: 410
Study: 18556222

Group type: EXPERIMENTAL
Intervention: Lysholm Knee Scale (modified version after removal of the swelling item)
Number of subjects: 157
Study: 17531731

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% and 0.1%
Number of subjects: 162
Study: 15087692

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: 40 mg esomeprazole daily
Number of subjects: 227
Study: 11304654

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) concurrently with meals
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) 2 hours after meals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aluminum hydroxide (Al(OH)3) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) with aluminum hydroxide (Al(OH)3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium acetate with aluminum hydroxide (Al(OH)3)
Number of subjects: 10
Study: 9484361

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg/day for 5 days, then 0.4 g/kg every 2 months for 2 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg) treatment and Placebo
Number of subjects: 40
Study: 8306818

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g) administered 30 min preoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mezlocillin (2 g) and oxacillin (1 g) administered over 24 h (3 injections)
Number of subjects: 100
Study: 2785872

Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia delivered through the right atrium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Number of subjects: 20
Study: 30993478

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: HIV voluntary counseling and testing (VCT)-only
Number of subjects: 43
Study: 28621019

Group type: EXPERIMENTAL
Intervention: Sit-to-stand test (STST)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 6-minute walking test (6MWT)
Number of subjects: 42
Study: 27234569

Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy-based group intervention delivered via videoconferencing in six 90 min group sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 24126897

Group type: EXPERIMENTAL
Intervention: Ascending intensity squat protocol (20% 1RM, 40% 1RM, 60% 1RM, 80% 1RM, and maximal isometric half-squat)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (resting on a chair after cycling and stretching)
Number of subjects: 14
Study: 22650118

Group type: EXPERIMENTAL
Intervention: Soothing‐liver and regulating‐mind group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Non‐acupoint‐shallow‐puncturing group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Acupoint‐shallow‐puncturing group
Number of subjects: 163
Study: 20939985

Group type: EXPERIMENTAL
Intervention: Pihui Fanggan Sachet (PHFGS) for 45 days
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Pihui Fanggan Sachet (PHFGS) in immunocompromised mice for one week
Number of subjects: 239

Group type: COMPARATOR
Intervention: Normal control group (no treatment)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Normal mice (no treatment)
Number of subjects: 239
Study: 18036453

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 12056

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12056
Study: 15830249

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12432437

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered intravenously (IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered subcutaneously (SC)
Number of subjects: 12
Study: 10354876

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Arthrography
Number of subjects: 104
Study: 7486743

Group type: EXPERIMENTAL
Intervention: Dynamic grip strength measurement with forearm rotation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Static grip strength measurement
Number of subjects: 15
Study: 2176097

Group type: EXPERIMENTAL
Intervention: 1% lidocaine, 3 mg/kg, diluted with physiological saline solution (pH = 6.63 +/‐ 0.05)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 1% lidocaine, 3 mg/kg, diluted with 1.4% sodium bicarbonate (pH = 7.34 +/‐ 0.05)
Number of subjects: 31
Study: 7010531

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (Duogastrone)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 60
Study: 30230047

Group type: EXPERIMENTAL
Intervention: Clarithromycin added to VCD (cyclophosphamide-bortezomib-dexamethasone)
Number of subjects: 58

Group type: COMPARATOR
Intervention: VCD (cyclophosphamide-bortezomib-dexamethasone) without clarithromycin
Number of subjects: 58
Study: 29235594

Group type: EXPERIMENTAL
Intervention: Fat-enriched pudding (FEP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-fat control pudding (CP)
Number of subjects: 19
Study: 27274092

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bag-Valve-Mask (BVM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) and Bag-Valve-Mask (BVM)
Number of subjects: 40
Study: 25282285

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 7155

Group type: COMPARATOR
Intervention: Simulated ACCP management protocol
Number of subjects: 7155

Group type: EXPERIMENTAL
Intervention: Diameter‐based protocol with volumetry-based nodule diameter
Number of subjects: 7155

Group type: EXPERIMENTAL
Intervention: Volume-based protocol (with thresholds based on lung cancer probability)
Number of subjects: 7155
Study: 23045588

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4760

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 4760

Group type: COMPARATOR
Intervention: Normal BMI (< 25 kg/m²)
Number of subjects: 4760

Group type: COMPARATOR
Intervention: Overweight (BMI 25 to < 30 kg/m²)
Number of subjects: 4760
Study: 20182846

Group type: EXPERIMENTAL
Intervention: Manganese chloride tetrahydrate (Bothdel Oral Solution 10) (MCT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ferric ammonium citrate (FerriSeltz powder 20%) (FAC)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No agent
Number of subjects: 57
Study: 17287847

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 362
Study: 16122538

Group type: EXPERIMENTAL
Intervention: Dual-focus schema therapy (DFST)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard group substance abuse counseling (SAC)
Number of subjects: 52
Study: 12031372

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride alone
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride and ciprofloxacin combined
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 184
Study: 11037095

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Eyes moving
Number of subjects: 35
Study: 8810174

Group type: EXPERIMENTAL
Intervention: Suxamethonium (succinylcholine chloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 1317767

Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 8
Study: 3006228

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31461577

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) at 10‐20% maximal voluntary contraction level
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group with visible or palpable level of muscle contraction
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 29357313

Group type: EXPERIMENTAL
Intervention: UC plus APP‐Me (automated short messaging system)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 240
Study: 26398704

Group type: EXPERIMENTAL
Intervention: Protocolized care
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1243
Study: 24425420

Group type: EXPERIMENTAL
Intervention: Generalized CFAE ablation + PVI
Number of subjects: 86

Group type: COMPARATOR
Intervention: Selective CFAE ablation targeting continuous electric activity + PVI
Number of subjects: 86
Study: 22081113

Group type: EXPERIMENTAL
Intervention: Epidrum
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (loss of resistance or hanging drop technique)
Number of subjects: 80
Study: 21108431

Group type: EXPERIMENTAL
Intervention: Molecular Resonance (MR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Monopolar Cautery (MPC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Coblation (CAT)
Number of subjects: 96
Study: 18202666

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 60
Study: 16457423

Group type: EXPERIMENTAL
Intervention: Active relaxation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Passive relaxation
Number of subjects: 58
Study: 13130405

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10836915

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg or 800 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (prophylaxis)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ciprofloxacin (prophylaxis)
Number of subjects: 42
Study: 8862238

Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 665

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 665
Study: 1611641

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three times daily)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 488

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 488
Study: 29679416

Group type: EXPERIMENTAL
Intervention: Bacterial culture sampling at pre-, intra-, and post-operative time points
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Identification of bacterial isolates including MRSA and ESBL-producers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Assessment of bacterial contamination and its relation to SSI
Number of subjects: 31
Study: 28654918

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg b.i.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg b.i.d.
Number of subjects: 18
Study: 26472682

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: HFrEF
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Combined biomarkers
Number of subjects: 570

Group type: COMPARATOR
Intervention: Cystatin-C
Number of subjects: 570

Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 570
Study: 23747790

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Nesiritide and Placebo
Number of subjects: 7141
Study: 21402642

Group type: EXPERIMENTAL
Intervention: Fortified mother's milk (group B)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Unfortified mother's milk (group A)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Preterm formula (group C)
Number of subjects: 320
Study: 19951447

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once a day
Number of subjects: 3161

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (recommended dose)
Number of subjects: 3161
Study: 17535624

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate 200 mg TDS for 2 weeks pre-operatively
Number of subjects: 49

Group type: COMPARATOR
Intervention: No iron therapy
Number of subjects: 49
Study: 14566032

Group type: EXPERIMENTAL
Intervention: Therapeutic tape (patellar realignment and soft-tissue unloading)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (placebo) tape and no tape
Number of subjects: 105
Study: 11445676

Group type: EXPERIMENTAL
Intervention: Immediate culture (H0)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Delayed culture (H24)
Number of subjects: 68
Study: 12515413

Group type: EXPERIMENTAL
Intervention: Motivational video package intervention
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Peer-counseling intervention
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both interventions (motivational video and peer counseling)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 115
Study: 8035916

Group type: EXPERIMENTAL
Intervention: IV penicillin G (3 g q 6 h)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral doxycycline (200 mg q 24 h)
Number of subjects: 54
Study: 3141219

Group type: EXPERIMENTAL
Intervention: 180 micrograms norgestimate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 250 micrograms norgestimate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 31794039

Group type: EXPERIMENTAL
Intervention: Gamification intervention in nursing education
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no gamification)
Number of subjects: 191
Study: 28422462

Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean with Premium plaque control brush head (SPC)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Oral-B 7000 with CrossAction brush head (OCA)
Number of subjects: 284
Study: 26463446

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 1 Hz for 20 sessions to the temporoparietal junction ipsilateral to the symptomatic ear.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard corticosteroid therapy (SCT) and hyperbaric oxygen (HBO) therapy without rTMS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (SPECT) measurements in a subgroup of patients receiving rTMS.
Number of subjects: 0
Study: 23628132

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 weekly for 8 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Multivitamin supplement containing 400 IU vitamin D3/d
Number of subjects: 160
Study: 21342321

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 32
Study: 19644396

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 98
Study: 17388703

Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment
Number of subjects: 1708
Study: 15041583

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11720431

Group type: EXPERIMENTAL
Intervention: Paclitaxel formulated in polysorbate 80
Number of subjects: 6

Group type: COMPARATOR
Intervention: Paclitaxel formulated in Cremophor EL 15 ml m(‐2)
Number of subjects: 6
Study: 9205939

Group type: EXPERIMENTAL
Intervention: Atenolol (n = 9)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Zofenopril (n = 25)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (n = 29 controls)
Number of subjects: 34
Study: 7835804

Group type: EXPERIMENTAL
Intervention: Screening for ovarian cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3295122

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50